Novo Nordisk A/S – aktietilbagekøbsprogram
/
Date23 Dec 2016
Selskabsmeddelelse nr. 89 / 2016.pdf Bagsværd, 2016-12-23 – Den 28. oktober 2016 iværksatte Novo Nordisk et aktietilbagekøbsprogram i overensstemmelse med artikel 5 i Europa-Parlamentet og... Read More →
Novo Nordisk A/S – Share repurchase programme
/
Date23 Dec 2016
Company announcement no. 89 / 2016.pdf Bagsværd, Denmark, 23 December 2016 – On 28 October 2016, Novo Nordisk initiated a share repurchase programme in accordance... Read More →
Hybrid’s Technology Is Featured In Prestigious European Polymer Journal
/
Date23 Dec 2016
SAN FRANCISCO, Dec. 23, 2016 (GLOBE NEWSWIRE) — Hybrid Coating Technologies Inc. (OTC Pink:HCTI) is pleased to announce that its Green Polyurethane technology was recently... Read More →
Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
/
Date23 Dec 2016
SAN DIEGO, Dec. 23, 2016 (GLOBE NEWSWIRE) — Neothetics, Inc. (NASDAQ:NEOT) today announced the initiation of the Phase 2 proof of concept trial, LIPO-202-CL-31, for... Read More →
Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases
/
Date23 Dec 2016
Press Release (PDF).pdf ChemoCentryx to retain commercialization rights in the United States and China, Vifor Pharma gains rights in all other markets ChemoCentryx to receive... Read More →
Progenics Pharmaceuticals Announces Independent Committee’s Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404
/
Date22 Dec 2016
NEW YORK, Dec. 22, 2016 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other technologies for targeting and treating... Read More →
Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases
/
Date22 Dec 2016
– ChemoCentryx to retain commercialization rights in the United States and China, Vifor Pharma gains rights in all other markets – – ChemoCentryx to receive... Read More →
IBRI Drives New Collaboration Model Targeting Type 2 Diabetes
/
Date22 Dec 2016
INDIANAPOLIS, Ind., Dec. 22, 2016 (GLOBE NEWSWIRE) — The Indiana Biosciences Research Institute (IBRI) today announced a new collaboration with Eli Lilly and Company, Roche... Read More →
NeuroDerm Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
/
Date22 Dec 2016
REHOVOT, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) — NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today... Read More →
Mithra Pharmaceuticals: MITHRA LAUNCHES ITS PRODUCT TIBELIA ON THE GLOBAL MARKET
/
Date22 Dec 2016
PRESS RELEASE Mithra launches ITS product Tibelia[1] on the GLOBAL market Mithra Pharmaceuticals received 14 Marketing Authorizations (MA) in 12 European countries... Read More →